The COMPASSION16 trial showed survival benefits of cadonilimab plus standard therapy in advanced cervical cancer. Here, subgroup analysis confirms consistent progression-free and overall survival improvements across diverse patient profiles.
- Yang Sun
- Hongying Yang
- Xiaohua Wu